Controlled Substances: Proposed Aggregate Production Quotas for 2008, 48683-48686 [E7-16729]

Agencies

• Drug Enforcement Administration
• Department of Justice

[Federal Register Volume 72, Number 164 (Friday, August 24, 2007)]
[Notices]
[Pages 48683-48686]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-16729]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-307P]


Controlled Substances: Proposed Aggregate Production Quotas for 
2008

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed year 2008 aggregate production quotas.

-----------------------------------------------------------------------

SUMMARY: This notice proposes initial year 2008 aggregate production 
quotas for controlled substances in schedules I and II of the 
Controlled Substances Act (CSA).

DATES: Comments or objections must be received on or before September 
14, 2007.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-307P'' on all written and electronic correspondence. 
Written comments being sent via regular mail should be sent to the 
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, Washington, DC 20537, Attention: DEA 
Federal Register Representative/ODL. Written comments sent via express 
mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, 
VA 22301. Comments may be directly sent to DEA electronically by 
sending an electronic message to dea.diversion.policy@usdoj.gov. 
Comments may also be sent electronically through https://
www.regulations.gov using the electronic comment form provided on that 
site. An electronic copy of this document is also available at the 
https://www.regulations.gov Web site. DEA will accept attachments to 
electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel 
file formats only. DEA will not accept any file format other than those 
specifically listed here.

FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, PhD, Chief, 
Drug and Chemical Evaluation Section, Drug Enforcement Administration, 
Washington, DC 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) 
requires that the Attorney General establish aggregate production 
quotas for each basic class of controlled substance listed in schedules 
I and II. This responsibility has been delegated to the Administrator 
of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated 
this function to the Deputy Administrator, pursuant to 28 CFR 0.104.
    The proposed year 2008 aggregate production quotas represent those 
quantities of controlled substances that may be produced in the United 
States in 2008 to provide adequate supplies of each substance for: The 
estimated medical, scientific, research, and industrial needs of the 
United States; lawful export requirements; and the establishment and 
maintenance of reserve stocks. These quotas do not include imports of 
controlled substances for use in industrial processes.
    In determining the proposed year 2008 aggregate production quotas, 
the Deputy Administrator considered the following factors: Total actual 
2006 and estimated 2007 and 2008 net disposals of each substance by all 
manufacturers; estimates of 2007 year-end inventories of each substance 
and of any substance manufactured from it and trends in accumulation of 
such inventories; product development requirements of both bulk and 
finished dosage form manufacturers; projected demand as indicated by 
procurement quota applications filed pursuant to 21 CFR 1303.12; and 
other pertinent information.
    Pursuant to 21 CFR 1303, the Deputy Administrator of the DEA will, 
in early 2008, adjust aggregate production quotas and individual 
manufacturing quotas allocated for the year based upon 2007 year-end 
inventory and actual 2007 disposition data supplied by quota recipients 
for each basic class of schedule I or II controlled substance.
    Therefore, under the authority vested in the Attorney General by 
Section 306 of the CSA of 1970 (21 U.S.C. 826), and delegated to the 
Administrator of the DEA by 28 CFR 0.100, and redelegated to the Deputy 
Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby 
proposes that the year 2008 aggregate production quotas for the 
following controlled substances, expressed in grams of anhydrous acid 
or base, be established as follows:

[[Page 48684]]



------------------------------------------------------------------------
                                                         Proposed year
               Basic class--Schedule I                    2008 quotas
                                                            (grams)
------------------------------------------------------------------------
2,5-Dimethoxyamphetamine.............................                  2
2,5-Dimethoxy-4-ethylamphetamine (DOET)..............                  2
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)                 10
3-Methylfentanyl.....................................                  2
3-Methylthiofentanyl.................................                  2
3,4-Methylenedioxyamphetamine (MDA)..................                 20
3,4-Methylenedioxy-N-ethylamphetamine (MDEA).........                 10
3,4-Methylenedioxymethamphetamine (MDMA).............                 22
3,4,5-Trimethoxyamphetamine..........................                  2
4-Bromo-2,5-dimethoxyamphetamine (DOB)...............                  2
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)...........                  7
4-Methoxyamphetamine.................................                 77
4-Methylaminorex.....................................                  2
4-Methyl-2,5-dimethoxyamphetamine (DOM)..............                 12
5-Methoxy-3,4-methylenedioxyamphetamine..............                  2
5-Methoxy-N,N-diisopropyltryptamine..................                  5
Acetyl-alpha-methylfentanyl..........................                  2
Acetyldihydrocodeine.................................                  2
Acetylmethadol.......................................                  2
Allylprodine.........................................                  2
Alphacetylmethadol...................................                  2
Alpha-ethyltryptamine................................                  2
Alphameprodine.......................................                  2
Alphamethadol........................................                  3
Alpha-methylfentanyl.................................                  2
Alpha-methylthiofentanyl.............................                  2
Alpha-methyltryptamine...............................                  5
Aminorex.............................................                  8
Benzylmorphine.......................................                  2
Betacetylmethadol....................................                  2
Beta-hydroxy-3-methylfentanyl........................                  2
Beta-hydroxyfentanyl.................................                  2
Betameprodine........................................                  2
Betamethadol.........................................                  2
Betaprodine..........................................                  2
Bufotenine...........................................                  8
Cathinone............................................                  3
Codeine-N-oxide......................................                302
Diethyltryptamine....................................                  2
Difenoxin............................................                 50
Dihydromorphine......................................          2,549,000
Dimethyltryptamine...................................                  3
Gamma-hydroxybutyric acid............................         23,600,000
Heroin...............................................                  5
Hydromorphinol.......................................              3,000
Hydroxypethidine.....................................                  2
Ibogaine.............................................                  1
Lysergic acid diethylamide (LSD).....................                 61
Marihuana............................................          4,500,000
Mescaline............................................                  2
Methaqualone.........................................                 10
Methcathinone........................................                  4
Methyldihydromorphine................................                  2
Morphine-N-oxide.....................................                310
N,N-Dimethylamphetamine..............................                  7
N-Ethylamphetamine...................................                  2
N-Hydroxy-3,4-methylenedioxyamphetamine..............                  2
Noracymethadol.......................................                  2
Norlevorphanol.......................................                 52
Normethadone.........................................                  2
Normorphine..........................................                 16
Para-fluorofentanyl..................................                  2
Phenomorphan.........................................                  2
Pholcodine...........................................                  2
Psilocybin...........................................                  7
Psilocyn.............................................                  7
Tetrahydrocannabinols................................            312,500
Thiofentanyl.........................................                  2
Trimeperidine........................................                  2
1-Phenylcyclohexylamine..............................                  2
Alfentanil...........................................              5,200
Alphaprodine.........................................                  2

[[Page 48685]]

 
Amobarbital..........................................                  3
Amphetamine (for sale)...............................         17,000,000
Amphetamine (for conversion).........................          5,000,000
Cocaine..............................................            286,000
Codeine (for sale)...................................         39,605,000
Codeine (for conversion).............................         59,000,000
Dextropropoxyphene...................................        106,000,000
Dihydrocodeine.......................................          1,200,000
Diphenoxylate........................................            828,000
Ecgonine.............................................             83,000
Ethylmorphine........................................                  2
Fentanyl.............................................          1,428,000
Glutethimide.........................................                  2
Hydrocodone (for sale)...............................         46,000,000
Hydrocodone (for conversion).........................          1,500,000
Hydromorphone........................................          3,300,000
Isomethadone.........................................                  2
Levo-alphacetylmethadol (LAAM).......................                  3
Levomethorphan.......................................                  5
Levorphanol..........................................              6,000
Lisdexamfetamine.....................................          6,200,000
Meperidine...........................................          9,753,000
Metazocine...........................................                  1
Methadone (for sale).................................         25,000,000
Methadone Intermediate...............................         26,000,000
Methamphetamine......................................          3,130,000
Methylphenidate......................................         50,000,000
Morphine (for sale)..................................         35,000,000
Morphine (for conversion)............................        100,000,000
Nabilone.............................................              3,002
Noroxymorphone (for sale)............................              1,002
Noroxymorphone (for conversion)......................          8,000,000
Opium................................................          1,400,000
Oxycodone (for sale).................................         70,000,000
Oxycodone (for conversion)...........................          3,100,000
Oxymorphone..........................................          1,800,000
Oxymorphone (for conversion).........................         11,000,000
Pentobarbital........................................         35,200,000
Phencyclidine........................................              2,021
Phenmetrazine........................................                  2
Racemethorphan.......................................                  2
Remifentanil.........................................              3,000
Secobarbital.........................................                  2
Sufentanil...........................................             10,300
Thebaine.............................................        126,000,000
------------------------------------------------------------------------

    The Deputy Administrator further proposes that aggregate production 
quotas for all other schedules I and II controlled substances included 
in 21 CFR 1308.11 and 1308.12 be established at zero.
    All interested persons are invited to submit their comments in 
writing or electronically regarding this proposal following the 
procedures in the addresses section of this document. A person may 
object to or comment on the proposal relating to any of the above-
mentioned substances without filing comments or objections regarding 
the others. If a person believes that one or more of these issues 
warrant a hearing, the individual should so state and summarize the 
reasons for this belief.
    In the event that comments or objections to this proposal raise one 
or more issues which the Deputy Administrator finds warrant a hearing, 
the Deputy Administrator shall order a public hearing by notice in the 
Federal Register, summarizing the issues to be heard and setting the 
time for the hearing.
    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866.
    This action does not preempt or modify any provision of state law; 
nor does it impose enforcement responsibilities on any state; nor does 
it diminish the power of any state to enforce its own laws. 
Accordingly, this action does not have federalism implications 
warranting the application of Executive Order 13132.
    The Deputy Administrator hereby certifies that this action will 
have no significant impact upon small entities whose interests must be 
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. 
The establishment of aggregate production quotas for schedules I and II 
controlled substances is mandated by law and by international treaty 
obligations. The quotas are necessary to provide for the estimated 
medical, scientific, research and industrial needs of the United 
States, for export requirements and the establishment and maintenance 
of reserve stocks. While aggregate production quotas are of primary 
importance to large manufacturers, their impact upon small entities is 
neither negative nor beneficial. Accordingly, the Deputy Administrator 
has determined that this action does not require a regulatory 
flexibility analysis.

[[Page 48686]]

    This action meets the applicable standards set forth in sections 
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
    This action will not result in the expenditure by state, local, and 
tribal governments, in the aggregate, or by the private sector, of 
$120,000,000 or more in any one year, and will not significantly or 
uniquely affect small governments. Therefore, no actions were deemed 
necessary under the provisions of the Unfunded Mandates Reform Act of 
1995.
    This action is not a major rule as defined by section 804 of the 
Small Business Regulatory Enforcement Fairness Act of 1996. This action 
will not result in an annual effect on the economy of $100,000,000 or 
more; a major increase in costs or prices; or significant adverse 
effects on competition, employment, investment, productivity, 
innovation, or on the ability of United States-based companies to 
compete with foreign-based companies in domestic and export markets.

    August 15, 2007.
Michele M. Leonhart,
Deputy Administrator.
 [FR Doc. E7-16729 Filed 8-23-07; 8:45 am]
BILLING CODE 4410-09-P